(Q37799934)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Optimal treatment for recurrent/metastatic head and neck cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

J B Vermorken

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

21 Suppl 7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

vii252-61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

Head and neck cancer: changing epidemiology, diagnosis, and treatment

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Medical treatment in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Taxanes in the treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Targeted therapies in head and neck cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Panitumumab a novel drug in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ453

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ453

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20943624%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference